Intra-silicone Oil Injection of Methotrexate in Retinal Reattachment Surgery for Proliferative Vitreoretinopathy

References

• Pastor JC, De La Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127–144.
   PubMed Web of Science ®Google Scholar
• Leiderman YI, Miller JW. Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol. 2009;24(2):62–69. doi:10.1080/08820530902800082.
   PubMed Web of Science ®Google Scholar
• Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina. 1997;17:44–50.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139.
   PubMed Web of Science ®Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ, Doolittle, N. D., Seigal, T., Neuwelt, T. A., Pe’er, J. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709–1716.
   PubMed Web of Science ®Google Scholar
• Taylor SRJ, Banker A, Schlaen A, Couto, C., Matthe, E., Jpshi, L., Menezo, V., Nguyen, E., Tomkins-Netzer, O., Bar, A., Morarji, J Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina. 2013;33(10):2149–2154. doi:10.1097/IAE.0b013e31828ac07d.
   PubMed Web of Science ®Google Scholar
• Hardwig PW, Pulido JS, Bakri SJ. The safety of intraocular methotrexate in silicone-filled eyes. Retina. 2008;28(8):1082–1086. doi:10.1097/IAE.0b013e3181754231.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani K, Modarres M, Hadavandkhani A, Karimi Moghaddam A. Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy. Eye. 2015;29(9):1199–1203. doi:10.1038/eye.2015.114.
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Golabi S, Modarres M. Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study. Graefe’s Arch Clin Exp Ophthalmol. 2016;254(11):2159–2164. doi:10.1007/s00417-016-3374-2.
   PubMed Web of Science ®Google Scholar
• Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016;10:1811–1817. doi:10.2147/OPTH.S111893.
   PubMed Web of Science ®Google Scholar
• Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159–165.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (Lond). 2014;28(5):576–580. doi:10.1038/eye.2014.21.
   PubMed Web of Science ®Google Scholar
• Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RHY, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111(12):2240–2245. doi:10.1016/j.ophtha.2004.05.036.
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy. A randomized clinical trial. Ophthalmology. 2008;115(11):1938–1943. doi:10.1016/j.ophtha.2008.05.016.
   PubMed Web of Science ®Google Scholar
• Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res. 2014;40:16–34. doi:10.1016/j.preteyeres.2013.12.006.
   PubMed Web of Science ®Google Scholar
• Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4(4):266–273. doi:10.1186/ar419.
   PubMedGoogle Scholar
• Taylor SRJ, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular Edema. Ophthalmology. 2009;116(4):797–801. doi:10.1016/j.ophtha.2008.10.033.
   PubMed Web of Science ®Google Scholar
• Amarnani D, Machuca-Parra AI, Wong LL, Marko CK, Stefater JA, Stryjewski TP, Eliott D, Arboleda-Velasquez JF, Kim LA Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Investig Ophthalmol Vis Sci. 2017;58(10):3940–3949. doi:10.1167/iovs.16-20912.
   PubMed Web of Science ®Google Scholar
• Asaria RHY, Gregor ZJ. Simple retinal detachments: identifying the at-risk case. Eye. 2002;16(4):404–410. doi:10.1038/sj.eye.6700189.
   PubMed Web of Science ®Google Scholar
• Lean JS, Boone DC, Azen SP Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial: silicone study report 1. Arch Ophthalmol. 1992;110(6):770–779.
   PubMedGoogle Scholar
• Garweg JG, Tappeiner C, Halberstadt M. Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol. 2013;58(4):321–329. doi:10.1016/j.survophthal.2012.12.004.
   PubMed Web of Science ®Google Scholar
• Kojima S, Yamada T, Tamai M. Quantitative analysis of interleukin-6 in vitreous from patients with proliferative vitreoretinal diseases. Jpn J Ophthalmol. 2001;45:40–45.
   PubMed Web of Science ®Google Scholar
• Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol. 1993;77:731–733.
   PubMed Web of Science ®Google Scholar